Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 382

1.

Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.

Xargay-Torrent S, López-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roué G, Campo E, Colomer D.

Clin Cancer Res. 2013 Feb 1;19(3):586-97. doi: 10.1158/1078-0432.CCR-12-1935. Epub 2012 Dec 11.

2.
3.

Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.

Udi J, Schüler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, Schnerch D, Follo M, Wäsch R, Engelhardt M.

Br J Haematol. 2013 Apr;161(1):104-16. doi: 10.1111/bjh.12226. Epub 2013 Feb 6.

PMID:
23384035
4.

Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.

Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G.

Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.

5.

Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.

Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I, Rosich L, Campo E, Roué G, Colomer D.

Clin Cancer Res. 2011 Jun 15;17(12):3956-68. doi: 10.1158/1078-0432.CCR-10-3412. Epub 2011 Jun 7.

6.

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.

Kim A, Seong KM, Kang HJ, Park S, Lee SS.

Oncotarget. 2015 Nov 10;6(35):38225-38. doi: 10.18632/oncotarget.5425.

7.

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.

Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K.

Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.

8.

Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.

Prasad A, Shrivastava A, Papadopoulos E, Kuzontkoski PM, Reddy MV, Gillum AM, Kumar R, Reddy EP, Groopman JE.

Clin Cancer Res. 2013 Jan 1;19(1):85-95. doi: 10.1158/1078-0432.CCR-12-1425. Epub 2012 Nov 1.

9.

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D.

Blood. 2006 Jan 1;107(1):257-64. Epub 2005 Sep 15.

10.

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.

Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, Moehler M, Schimanski CC.

Int J Colorectal Dis. 2013 Mar;28(3):385-98. doi: 10.1007/s00384-012-1551-2. Epub 2012 Sep 15.

11.

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T.

Br J Cancer. 2011 Jan 4;104(1):91-100. doi: 10.1038/sj.bjc.6606007. Epub 2010 Dec 7.

12.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D.

Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.

13.

Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.

Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V.

Blood. 2012 Oct 25;120(17):3491-500. doi: 10.1182/blood-2012-02-412643. Epub 2012 Sep 6.

14.

Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.

Müller A, Zang C, Chumduri C, Dörken B, Daniel PT, Scholz CW.

Int J Cancer. 2013 Oct 15;133(8):1813-24. doi: 10.1002/ijc.28206. Epub 2013 Jun 15.

15.

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.

Leukemia. 2013 Aug;27(8):1677-87. doi: 10.1038/leu.2013.28. Epub 2013 Jan 30.

PMID:
23360848
16.

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.

Zhao LL, Liu YF, Peng LJ, Fei AM, Cui W, Miao SC, Hermine O, Gressin R, Khochbin S, Chen SJ, Wang J, Mi JQ.

Cancer Med. 2015 Nov;4(11):1754-66. doi: 10.1002/cam4.511. Epub 2015 Aug 26.

17.

Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.

Retnakumari AP, Hanumanthu PL, Malarvizhi GL, Prabhu R, Sidharthan N, Thampi MV, Menon D, Mony U, Menon K, Keechilat P, Nair S, Koyakutty M.

Mol Pharm. 2012 Nov 5;9(11):3062-78. doi: 10.1021/mp300172e. Epub 2012 Oct 5.

PMID:
22971013
18.

Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN.

Clin Cancer Res. 2010 Oct 1;16(19):4742-54. doi: 10.1158/1078-0432.CCR-10-0529. Epub 2010 Jul 20.

19.

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.

Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.

PMID:
20799354
20.

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA.

Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12.

Supplemental Content

Support Center